{"created":"2023-05-15T14:42:45.445256+00:00","id":58587,"links":{},"metadata":{"_buckets":{"deposit":"0a00629f-d4c5-495e-a22c-5f11f4bda68a"},"_deposit":{"created_by":1,"id":"58587","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"58587"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00058587","sets":["11"]},"author_link":["585552","585550","585553","585555","585554","585551"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"28","bibliographicPageStart":"22","bibliographicVolumeNumber":"15","bibliographic_titles":[{"bibliographic_title":"分子精神医学"}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"現在上市されている抗精神病は共通してドーパミンD2受容体（D2-R）に結合して薬効を発現する．このことは臨床のD2-R陽電子断層撮像（positron emission tomography; PET） 法によるD2-R占有率測定で証明されており，PETを利用した新規抗精神病薬の開発も行われている．本稿では抗精神病薬のD2-R占有率を中心に我々および他施設の研究結果について紹介する．","subitem_description_type":"Abstract"}]},"item_10004_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"先端医学社"}]},"item_10004_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1345-9082","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"前田, 純"}],"nameIdentifiers":[{"nameIdentifier":"585550","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"樋口, 真人"}],"nameIdentifiers":[{"nameIdentifier":"585551","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原, 哲也"}],"nameIdentifiers":[{"nameIdentifier":"585552","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"前田 純","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"585553","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"樋口 真人","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"585554","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"須原 哲也","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"585555","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"抗精神病薬の臨床開発における分子神経イメージングの役割","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"抗精神病薬の臨床開発における分子神経イメージングの役割"}]},"item_type_id":"10004","owner":"1","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-11-05"},"publish_date":"2015-11-05","publish_status":"0","recid":"58587","relation_version_is_last":true,"title":["抗精神病薬の臨床開発における分子神経イメージングの役割"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T22:14:23.129193+00:00"}